We are live on ! Find out more
GDTC icon

CytoMed Therapeutics

6 hedge funds and large institutions have $116K invested in CytoMed Therapeutics in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,561% more capital inflows, than outflows

Capital inflows: $120K | Capital outflows: $7.24K

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more funds holding

Funds holding: 3 → 6 (+3)

1.05% more ownership

Funds ownership: 0.1% → 1.15% (+1%)

Holders
6
Holders Change
+3
Holders Change %
+100%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

GDTC Hedge Fund Activity: Q3 2026 in Review

6 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q3 2026, worth a combined $116K — up 845% from $12.2K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GDTC positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $31.3K. The largest seller was Axiom Investment Management, exiting entirely with an estimated $7.24K sold.

  • 6 institutional investors held CytoMed Therapeutics (GDTC) as of Q3 2026, up from 3 in Q2 2026.
  • Funds reported $116K of CytoMed Therapeutics stock for Q3 2026, up 845% quarter-over-quarter.
  • 4 funds opened new CytoMed Therapeutics positions in Q3 2026 and 1 closed out, a net change of +3 holders.
  • The largest CytoMed Therapeutics buyer in Q3 2026 was UBS Group, an estimated $31.3K added.
  • The largest CytoMed Therapeutics seller in Q3 2026 was Axiom Investment Management, an estimated $7.24K sold.

Based on aggregated 13F filings for Q3 2026.